This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scheffler, P. Articles by Schieffer, H. Search for Related Content PubMed PubMed Citation Articles by Scheffler, P. Articles by Schieffer, H.

Circulation, Vol 90, 818-822, Copyright © 1994 by American Heart Association

ARTICLES

Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training

P Scheffler, D de la Hamette, J Gross, H Mueller and H Schieffer
University Hospital of Saarland, Germany.

In a randomized open study, the combination of either prostaglandin E1 (PGE1) or pentoxifylline with controlled vascular training was compared with vascular training alone in patients with peripheral arterial occlusive disease in stage IIb. Forty-four patients were randomly assigned to treatment either of intensive vascular training alone (n = 15) or in combination with either i.v. pentoxifylline (200 mg over 2 hours BID, n = 15) or PGE1 (40 micrograms over 2 hours BID, n = 14). The basic therapy was a well-defined routine for vascular training, which was identical for all groups. The duration of therapy was 4 weeks. In all three test groups, there was a significant increase in the walking distance. There was a 119% increase in symptom-free walking distance in the exercise-only group. In comparison with exercise alone, the additional administration of pentoxifylline produced no greater effect; the increase was 105%. In contrast, administration of PGE1 combined with exercise achieved a remarkable improvement of 604%. Between-group comparison revealed the significant superiority of treatment with PGE1 (P < .05). During the 1-year follow-up, there was a reduction in the walking performance in all groups, albeit of variable extent. In the exercise-only and the pentoxifylline groups, the maintained increase in walking distance was only 30% compared with baseline values before the beginning of therapy. In the PGE1 group, on the other hand, the maintained improvement was 149%. Nine of 14 patients were still in stage IIa of peripheral arterial occlusive disease 1 year after PGE1 therapy.

This article has been cited by other articles:

				M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]

				K. Amendt PGE1 and Other Prostaglandins in the Treatment of Intermittent Claudication: A Meta-analysis Angiology, July 1, 2005; 56(4): 409 - 415. [Abstract] [PDF]

				G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]

				C. F. Kugler and G. Rudofsky The challenges of treating peripheral arterial disease Vascular Medicine, May 1, 2003; 8(2): 109 - 114. [Abstract] [PDF]

				M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119 (2009): 283S - 299S. [Full Text] [PDF]

				G. Belcaro, A.N. Nicolaides, G. Cipollone, G. Laurora, L. Incandela, M. Cazaubon, A. Barsotti, A. Ledda, B.M. Errichi, U. Cornelli, et al. Nomograms Used to Define the Short-Term Treatment with PGE1 in Patients with Intermittent Claudication and Critical Ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study Angiology, August 1, 2000; 51(8): S3 - S14. [Abstract] [PDF]

				G. Belcaro, A.N. Nicolaides, G. Agus, M.R. Cesarone, G. Geroulakos, L. Pellegrini, M.T. De Sanctis, L. Incandela, A. Ricci, P. Mondani, et al. PGE 1 Treatment of Severe Intermittent Claudication (Short-Term Versus Long-Term, Associated with Exercise): Efficacy and Costs in a 20-Week, Randomized Trial Angiology, August 1, 2000; 51(8): S15 - S26. [Abstract] [PDF]

				R. A. Mangiafico, R. Messina, T. Attina, S. Dell'Arte, L. Giuliano, L. S. Malatino, and R.A. Mangiafico Impact of a 4-Week Treatment with Prostaglandin E1 on Health-Related Quality of Life of Patients with Intermittent Claudication Angiology, June 1, 2000; 51(6): 441 - 449. [Abstract] [PDF]

				B. Girolami, E. Bernardi, M. H. Prins, J. W. ten Cate, R. Hettiarachchi, P. Prandoni, A. Girolami, and H. R. Buller Treatment of Intermittent Claudication With Physical Training, Smoking Cessation, Pentoxifylline, or Nafronyl: A Meta-analysis Arch Intern Med, February 22, 1999; 159(4): 337 - 345. [Abstract] [Full Text] [PDF]

				G. Belcaro, G. Laurora, A.N. Nicolaides, G. Agus, M.R. Cesarone, M.T. DeSanctis, L. Incandela, A. Ricci, M. Cazaubon, E. Ippolito, et al. Treatment of Severe Intermittent Claudication with PGE1 A Short-Term vs a Long-Term Infusion Plan A 20-Week, European Randomized Trial Analysis of Efficacy and Costs Angiology, November 1, 1998; 49(11): 885 - 895. [Abstract] [PDF]